Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Myeloid 1

Conditions

Breast Neoplasms 1152Prostatic Neoplasms 642Neoplasms 581Carcinoma, Non-Small-Cell Lung 488Multiple Myeloma 482Leukemia, Myeloid, Acute 461Leukemia 418Lung Neoplasms 399Lymphoma 381Leukemia, Lymphocytic, Chronic, B-Cell 332Precursor Cell Lymphoblastic Leukemia-Lymphoma 327Lymphoma, Non-Hodgkin 326Colorectal Neoplasms 310Pancreatic Neoplasms 306Neoplasm Metastasis 302Myelodysplastic Syndromes 301Melanoma 285Hodgkin Disease 253Head and Neck Neoplasms 249Brain Neoplasms 230Lymphoma, Follicular 224Recurrence 220Ovarian Neoplasms 220Glioblastoma 215Lymphoma, Mantle-Cell 211Lymphoma, Large B-Cell, Diffuse 209Squamous Cell Carcinoma of Head and Neck 176Colonic Neoplasms 162Carcinoma, Renal Cell 157Carcinoma, Hepatocellular 154

Interventions

Lenalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Has results × Erdheim-Chester Disease × Clear all
NCT02523040 2025-12-10

Lenalidomide for Adult Histiocyte Disorders

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
12 enrolled 14 charts
MyeloidSarcoma

Histiocytosis, Langerhans-Cell, Erdheim-Chester Disease, Histiocytic Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡